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Summary
Background Persistent inﬂ ammation has been proposed to contribute to various stages in the pathogenesis of 
cardiovascular disease. Interleukin-6 receptor (IL6R) signalling propagates downstream inﬂ ammation cascades. To 
assess whether this pathway is causally relevant to coronary heart disease, we studied a functional genetic variant 
known to aﬀ ect IL6R signalling.
Methods In a collaborative meta-analysis, we studied Asp358Ala (rs2228145) in IL6R in relation to a panel of 
conventional risk factors and inﬂ ammation biomarkers in 125 222 participants. We also compared the frequency of 
Asp358Ala in 51 441 patients with coronary heart disease and in 136 226 controls. To gain insight into possible 
mechanisms, we assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation 
of interleukin 6.
Findings The minor allele frequency of Asp358Ala was 39%. Asp358Ala was not associated with lipid concentrations, 
blood pressure, adiposity, dysglycaemia, or smoking (p value for association per minor allele ≥0·04 for each). By 
contrast, for every copy of 358Ala inherited, mean concentration of IL6R increased by 34·3% (95% CI 30·4–38·2) and 
of interleukin 6 by 14·6% (10·7–18·4), and mean concentration of C-reactive protein was reduced by 7·5% (5·9–9·1) 
and of ﬁ brinogen by 1·0% (0·7–1·3). For every copy of 358Ala inherited, risk of coronary heart disease was reduced 
by 3·4% (1·8–5·0). Asp358Ala was not related to IL6R mRNA levels or interleukin-6 production in monocytes.
Interpretation Large-scale human genetic and biomarker data are consistent with a causal association between IL6R-
related pathways and coronary heart disease. 
Funding British Heart Foundation; UK Medical Research Council; UK National Institute of Health Research, 
Cambridge Biomedical Research Centre; BUPA Foundation.
Introduction
Although the hypothesis that persistent inﬂ ammation 
contributes to various stages in the pathogenesis of 
cardiovascular disease is supported by observational and 
experimental studies in human beings and animals,1,2 
causality has not been established. Data from observa-
tional epidemiological studies have suggested that circu-
lating concentrations of liver-derived inﬂ am mation 
bio markers (eg, C-reactive protein, ﬁ brinogen) are associ-
ated with subsequent risk of coronary heart disease.3–5 
However, the likelihood of a direct causal role for these 
particular downstream inﬂ ammation bio markers has 
been reduced because inherited DNA variations associated 
with them have not been linked to coronary heart disease.6–8 
Clinical investigation of solu ble concen trations of proxi-
mal regu lators of inﬂ am mation cascades, such as the 
signalling of interleukin-6 receptor (IL6R) pathways, can 
be diﬃ  cult because these factors are prone to ﬂ uctuation 
in the circulation.3 Consequently, to help to evaluate the 
rele vance of proximal inﬂ ammatory mediators to coronary 
heart disease, studies of the genetic deter minants of these 
factors might be informative, since such genetic variants 
are ﬁ xed at conception and are indicators of lifelong 
(rather than transient) inﬂ ammation status.6
In classic IL6R signalling, soluble interleukin 6 
acti vates the membrane-bound receptor in hepatocytes 
and leucocytes, thereby initiating downstream proinﬂ am-
matory cascades that increase hepatic production of 
C-reactive protein, ﬁ brinogen, and other acute-phase 
reactants.9,10 Cell-based experiments have suggested that 
the Asp358Ala (rs2228145, formerly known as rs8192284) 
variant in IL6R might impair classic IL6R signalling (and 
hence dampen inﬂ ammation) by reducing membrane-
bound IL6R levels.11–14 Although previous studies have 
reported associations between Asp358Ala (or variants 
closely linked with it) and circulating inﬂ ammation 
biomarkers,7,12,15–19 asthma,20 and some autoimmune 
diseases,21,22 associations of Asp358Ala with conventional 
cardiovascular risk factors or with risk of coronary heart 
disease have not been precisely characterised.7,23 To help 
to assess whether IL6R pathways are causally relevant to 
coronary heart disease, we analysed human genetic and 
biomarker data from more than 200 000 participants in a 
collaborative meta-analysis.
Methods
Study design
This meta-analysis had several interrelated components. 
First, we assessed associations of Asp358Ala (or two 
proxy genetic variants closely related to it) with 
sev eral inﬂ ammation biomarkers and conventional 
cardio vascular risk factors in studies including up to 
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125 222 participants without a history of cardiovascular 
disease. Second, to gain insight into possible mechan isms, 
we undertook functional studies in monocytes and 
macrophages. Third, we assessed Asp358Ala in relation to 
risk of coronary heart disease in a meta-analysis of 
51 441 patients with the disease and 136 226 controls to 
evaluate the previously suggested signal at this locus. 
Fourth, to compare the eﬀ ect of Asp358Ala on liver-derived 
inﬂ ammation biomarkers with the correspond ing physio-
logical relationships of these soluble bio mark ers with 
one another, we characterised the cross-sectional associ-
ations of circulating interleukin 6, C-reactive pro tein, 
and ﬁ brinogen concentrations and their associa tions 
with incident coronary heart disease risk in up to 
109 339 participants without a history of cardiovascular 
disease. Fifth, to compare the eﬀ ects of Asp358Ala on 
concentrations of inﬂ ammation bio markers and major 
lipids with those of tocilizumab, a monoclonal antibody 
that selectively inhibits IL6R, we analysed data for 
4394 patients with inﬂ ammatory condi tions enrolled in 
previous randomised placebo-controlled trials.
Contributing studies and data
For analyses of IL6R genotypes in relation to inﬂ ammation 
biomarkers, cardiovascular disease risk factors, and risk 
of coronary heart disease, we used systematic searches of 
the literature and registries of genetic studies to collate 
information from 46 studies with relevant summary-level 
data, as described in detail in the appendix pp 4–7, 20, 25. 
Studies provided data for Asp358Ala or, if this was not 
available, for either of two proxy variants highly correlated 
with rs2228145: rs4537545 or rs4129267 (r²=0·96 with 
each variant in white Europeans). Because of the high 
degree of linkage among these variants (appendix p 12), 
principal analyses were done for all three combined 
(sensitivity analyses assessed associations separately for 
each variant, where possible).
According to a uniform protocol, data were obtained 
from all studies, where available, for genotype fre-
quencies by categorical disease outcome (separately for 
myocardial infarction cases, non-overlapping coronary 
stenosis cases, and healthy controls); criteria used to 
diagnose coronary heart disease; circulating concen-
trations of soluble IL6R, interleukin 6, C-reactive protein, 
ﬁ brinogen, LDL cholesterol, HDL cholesterol, trigly-
cerides, and fasting glucose; measurements of systolic 
blood pressure, body-mass index (BMI), and waist 
circumference; and information about smoking status 
and history of diabetes (appendix pp 4–7). Data for 
inﬂ ammation biomarkers and conventional risk factors 
were from participants with no known history of 
cardiovascular disease at time of survey. Data for coronary 
heart disease derived from participants in case-control 
studies included myocardial infarction or coronary 
stenosis (details provided in appendix p 6). Data from 
published studies were extracted in duplicate by two 
independent reviewers. All tabular data provided by study 
authors were cross-checked with registry data and queried 
with authors of papers, where necessary. Contributing 
prospective studies recorded coronary heart disease 
outcomes through linkage with hospital discharge 
records, mortality registers, and active follow-up.
To investigate whether observed associations of 
Asp358Ala might be due to eﬀ ects on production of IL6R 
or interleukin 6 (rather than the shedding of membrane-
bound IL6R into circulation), we assessed IL6R genotype 
in relation to gene expression in monocytes and 
macrophages derived from 363 patients with premature 
myocardial infarction and 395 healthy blood donors, and 
to postlipopolysaccharide stimulation of interleukin 6 in 
monocytes derived from 205 separate healthy blood donors 
(details provided in appendix pp 3, 26). We validated these 
results by accessing further data for circulating monocytes 
from 1490 healthy participants in the Gutenberg Heart 
Study,24 as well as further publicly available gene expression 
datasets that include liver, lymphoblastoid, and T cells.25–28 
We did not undertake functional experiments to investigate 
whether Asp358Ala aﬀ ects shedding of membrane-bound 
IL6R, because such work has been done previously.11–13 For 
analyses of cross-sectional correlations of inﬂ ammation 
biomarkers with one another and of associations of these 
biomarkers with incident coronary heart disease, we 
accessed individual-level data from participants without 
known cardiovascu lar disease at the baseline survey of 
38 population-based long-term prospective studies (app en-
dix pp 8, 21).4 Such data for soluble IL6R concen tra tions 
were not available. For analyses of tocilizumab, we did 
systematic searches of published randomised trials, as 
described in detail in appendix pp 22–24. We invited 
investigators and trial sponsors to provide tabular data for 
trial protocols, treatment regimens, and levels of inﬂ am-
mation and lipid biomarkers. Data were included from all 
relevant trials reporting both pre-trial and post-trial mean 
(SD) biomarker concentrations.
Statistical analysis
We calculated estimates of association separately within 
each study before pooling across studies by ﬁ xed-eﬀ ect 
meta-analysis (supplementary analyses used random-
eﬀ ects models), using methods described previously.29 
Summary odds ratios (ORs) for coronary heart disease 
and diﬀ erences in mean levels by IL6R genotype and per 
minor allele were calculated compared with the common 
homozygotes. Analyses were done with original units 
and then presented as percentage diﬀ erences to enable 
comparisons across diﬀ erent biomarkers (calculated in 
reference to the weighted mean of each biomarker among 
common homozygotes). Cross-sectional associa tions 
among inﬂ ammation biomarkers were assessed with 
linear regression models to obtain means adjusted for 
age and sex. Biomarkers that were not normally 
distributed were analysed on a natural logarithmic 
scale. Hazard ratios for associations of biomarkers with 
incident coronary heart disease were calculated with Cox 
See Online for appendix
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proportional hazards models (adjusting for conventional 
cardiovascular disease risk factors) and then pooled 
across studies, as previously described.4
We assessed the eﬀ ect of tocilizumab intervention on 
inﬂ ammation and lipid biomarkers by calculating mean 
diﬀ erences before and after intervention within each trial 
group, then pooling ﬁ ndings across studies. Heterogeneity 
was assessed by the I² statistic,30 the Q statistic, and 
metaregression of prespeciﬁ ed groupings of study charac-
teristics including study design, location, genetic variants 
used, and study size. Small-study eﬀ ects were assessed 
with funnel plots and by comparison of pooled results 
from studies involving at least 500 coronary cases (or, for 
gene-intermediate phenotype investigations, at least 
1000 participants) with those from smaller studies. We 
separately analysed data for Asp358Ala and coronary heart 
disease in the 16 studies (84 796 partici pants) that had 
previously reported on this association (the hypo thesis-
generating set7,19,23) and 24 additional studies (102 871 further 
participants) that provided an independent test of this 
hypothesis. A consequence of this focused hypothesis 
testing of one genetic variant with risk of coronary heart 
disease is that adjustment for multiple testing was not 
needed, by contrast with hypothesis-free genome-wide 
association studies explor ing several hundred thousand 
variants. Analyses were done with Stata (version 11), two-
sided p values, and 95% CIs.
Role of the funding source
The sponsors of the study have no role in study design, 
data analysis, data interpretation, or writing of the report. 
Nadeem Sarwar, Adam Butterworth, and John Danesh 
had full access to all the data and had ﬁ nal responsibility 
for the decision to submit for publication.
Results
We meta-analysed data from 46 genetic epidemiological 
studies (204 930 participants), 30 classical observational 
epidemiological studies (109 339 participants), nine 
ran domised trials (4394 participants), and three 
explanatory functional studies (2372 participants), 
constituting 82 unique studies. Since more than 90% of 
these participants were of white European continental 
ancestry, there were insuﬃ  cient data from non-Europeans 
to enable detailed comparisons with people of other 
continental ancestries.
In people without coronary heart disease, the overall 
minor allele frequency of Asp358Ala was 39%, and this 
frequency was similar across contributing studies 
(appendix pp 4–5). IL6R genotype was not related to 
concentrations of LDL or HDL cholesterol, triglyceride, 
fasting glucose, systolic blood pressure, BMI, waist 
circumference, smoking status, or history of diabetes 
(p value for association per minor allele ≥0·04 for each; 
table). By contrast, carriers of 358Ala had signiﬁ cantly 
higher mean concentrations of soluble IL6R and 
interleukin 6 (both p<10–¹³) and signiﬁ cantly lower 
mean concentrations of C-reactive protein and 
ﬁ brinogen compared with non-carriers (both p<10–¹¹). 
The results were consistent with a per-allele model of 
inheritance (ﬁ gure 1). For every minor allele inherited, 
carriers had a 34·3% (95% CI 30·4–38·2) increase in 
mean concentration of soluble IL6R, a 14·6% 
(10·7–18·4) increase in mean interleukin 6, a 7·5% 
(5·9–9·1) reduction in mean C-reactive protein, and a 
1·0% (0·7–1·3) reduction in mean ﬁ brinogen (table).
Participants with 
available data
Percentage mean 
diﬀ erence or odds ratio 
(95% CI) per minor allele
p value for 
association
Inﬂ ammation markers
Soluble IL6R 1645 34·3% (30·4 to 38·2) 1·8×10⁶⁵
Interleukin 6 27 185 14·6% (10·7 to 18·4) 8·3×10¹⁴
C-reactive protein 83 948 –7·5% (–9·1 to –5·9) 1·6×10¹⁹
Fibrinogen 50 353 –1·0% (–1·3 to –0·7) 4·8×10¹²
Conventional vascular risk factors
LDL cholesterol 80 343 –0·03% (–0·3 to 0·3) 0·83
HDL cholesterol 95 970 0·07% (–0·1 to 0·4) 0·44
Triglyceride 94 473 –0·3% (–0·9 to 0·3) 0·28
Fasting glucose 51 109 0·02% (–0·2 to 0·3) 0·87
Systolic blood pressure 99 577 –0·1% (–0·3 to –0·01) 0·04
Body-mass index 122 222 0·01% (–0·1 to 0·2) 0·90
Waist circumference 81 492 0·2% (–0·01 to 0·3) 0·06
Ever vs never smokers 54 523 vs 54 817 0·98 (0·96 to 1·01) 0·07
History vs no history of diabetes 9722 vs 80 095 0·99 (0·96 to 1·03) 0·62
Odds ratios are presented for smoking status and history of diabetes. Analyses were undertaken with standardised units of 
measurement for each marker. To enable comparison of the magnitude of associations across several diﬀ erent markers, 
associations are presented as percentage diﬀ erences (calculated in reference to the weighted overall mean of each marker 
among the reference group). Details of the genotypes studied are provided in appendix p 12. IL6R=interleukin-6 receptor.
Table: Association of IL6R genotypes with levels of inﬂ ammation markers and conventional vascular 
risk factors
Figure 1: IL6R genotypes and circulating concentrations of inﬂ ammation markers
Analyses were undertaken with standardised units of measurement for each marker. To enable comparison of the 
magnitude of associations across several diﬀ erent markers, associations are presented as percentage diﬀ erences 
(calculated in reference to the weighted overall mean of each marker among the reference group). The number of 
participants with information about each marker is shown in the table. Details of the genotypes studied are 
provided in appendix p 12. Error bars show 95% CI. IL6R=interleukin-6 receptor. *Reference group (represented by 
a square with an arbitrary ﬁ xed size).
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Associations between Asp358Ala and each of inter-
leukin 6, C-reactive protein, and ﬁ brinogen concentration 
did not vary by the speciﬁ c variant assessed (ie, lead 
single nucleotide polymorphism or proxy variant) or the 
study design used, nor was there evidence of small-
study eﬀ ects (appendix p 13). Data were insuﬃ  cient for 
detailed analyses by ethnicity, although results remained 
unchanged when restricted to studies of people of 
predominantly white European descent (appendix p 9) 
and did not signiﬁ cantly diﬀ er when results were 
grouped by geographical location. There were too few 
data to enable such subanalyses for soluble IL6R. 
Asp358Ala was not associated with IL6R mRNA levels 
in monocytes or macrophages (appendix p 10), nor was 
any signiﬁ cant association seen in the range of tissues 
in publicly available gene expression datasets. Further-
more, Asp358Ala was not associated with inter leukin-6 
production by monocytes after lipo polysaccharide 
stimu lation (appendix p 14).
Risk of coronary heart disease was lower in carriers of 
358Ala compared with non-carriers. Again, there was 
evidence of a per-allele model of inheritance (ﬁ gure 2). 
Figure 3: (A) Cross-sectional associations between interleukin 6, C-reactive protein, and ﬁ brinogen concentrations in the general population and 
(B) associations of interleukin 6, C-reactive protein, and ﬁ brinogen concentrations with incident coronary heart disease
Adjusted for age, sex, smoking, body-mass index, diabetes status, systolic blood pressure, and total cholesterol. Studies included in these analyses had information on 
at least two of the biomarkers studied and had recorded at least ten incident coronary heart disease events during follow-up. Error bars show 95% CI.
–2 –1 0 1 2 3
0
0·5
1·0
1·5
A
Lo
g e
 in
te
rle
uk
in
 6
 (n
g/
L)
Loge C-reactive protein (mg/L)
C-reactive protein and interleukin 6
19 053 participants; r=0·49 (0·46–0·52)
Men
Women
6 8 10 12 14
1·0
1·5
2·0
2·5
B
H
az
ar
d 
ra
tio
Loge ﬁbrinogen (μmol/L)
Fibrinogen
59 378 participants, 21 cohorts
–2 –1 0 1 2 3
Loge C-reactive protein (mg/L)
C-reactive protein and fibrinogen
74 298 participants; r=0·48 (0·45–0·50)
–0·5 0 0·5 1 1·5 2
0
8·0
9·0
10·0
11·0
12·0
13·0
0
8·0
9·0
10·0
11·0
12·0
13·0
Fi
br
in
og
en
 (μ
m
ol
/L
)
Loge interleukin 6 (ng/L)
Interleukin 6 and fibrinogen
14 078 participants; r=0·35 (0·31–0·39)
–1 0 1 2
Loge C-reactive protein (mg/L)
C-reactive protein
109 339 participants, 38 cohorts
–0·5 0 0·5 1 1·5
Loge interleukin 6 (ng/L)
Interleukin 6
14 236 participants, 7 cohorts
Figure 2: IL6R genotypes and risk of coronary heart disease
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allele was 0·966 (95% CI 0·950–0·982, p=4·5×10–⁵). Details of the genotypes 
studied are provided in appendix p 12. Error bars show 95% CI. *Reference group 
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For every minor allele inherited, carriers had a 3·4% 
(1·8–5·0) reduction in risk of coronary heart disease. 
Results were similar in the 24 hypothesis-testing studies 
that did not contribute to previous analyses (4·2%, 
2·1–6·3), thereby providing independent conﬁ rmation of 
this association. Findings did not vary by the variant 
assessed, the type of coronary outcome recorded, or study 
design used, nor was there evidence of small-study eﬀ ects 
(appendix p 15). Results did not diﬀ er according to study 
location and were similar in analyses restricted to 
populations of white European descent.
Among people with no history of cardiovascular disease 
at the time of blood sampling, circulating concentrations 
of interleukin 6, C-reactive protein, and ﬁ brinogen were 
each positively associated with one another (ﬁ gure 3A). 
The age-adjusted and sex-adjusted partial correlation 
coeﬃ  cient was 0·49 (95% CI 0·46–0·52) between loge 
interleukin 6 and loge C-reactive protein, 0·35 (0·31–0·39) 
between loge interleukin 6 and ﬁ brinogen, and 0·48 
(0·45–0·50) between loge C-reactive protein and 
ﬁ brinogen. There were roughly log-linear associations 
between baseline concentrations of each of interleukin 6, 
C-reactive protein, and ﬁ brinogen and subsequent risk of 
coronary heart disease (ﬁ gure 3B).
Nine randomised trials of tocilizumab, involving 
4394 patients with rheumatoid arthritis or Crohn’s 
disease, were included in our analyses (appendix p 11). 
Original data were provided by investigators for ﬁ ve of 
these trials (4087 patients) and published data were 
abstracted for four trials (307 patients). Five of the nine 
trials also involved methotrexate use. In analyses 
of lipids, comparing post-treatment with pre-treatment 
levels, tocilizumab inter vention resulted in increased 
concentrations of total, LDL, and HDL cholesterol and 
triglycerides (appendix p 16), as well as increased 
concentrations of proximal inﬂ ammatory mediators 
(soluble IL6R and interleukin 6) and decreased concen-
trations of downstream mediators (C-reactive protein 
and ﬁ brinogen; appendix p 17). For some biomarker 
endpoints (eg, interleukin 6, IL6R, LDL cholesterol), 
there was substantial heterogeneity among the results of 
the contributing trials (appendix pp 18–19). However, 
most of the statistical scatter was due to only one or two 
of the trials, the omission of which did not aﬀ ect the 
overall results.
Discussion
Interest in the inﬂ ammation hypothesis of cardiovascular 
disease has intensiﬁ ed since the launch of phase 3 trials 
of various anti-inﬂ ammatory agents in the secondary 
prevention of cardiovascular disease, including two trials 
of darapladib (an inhibitor of lipoprotein-associated 
phospholipase A2),31 a trial of canakinumab (a monoclonal 
antibody to interleukin 1β),32 and a trial of low-dose 
methotrexate.33 Although this hypothesis has received 
some support from previous human genetic studies that 
implicate loci of potential relevance to inﬂ am mation, 
including CXCL12,34 ADAMTS7,35 SH2B3,34 and IL5,23 in 
coronary heart disease, such studies have not provided 
speciﬁ c insight into inﬂ ammation and coronary heart 
disease because the relevant genes (or causal alleles) in 
these loci still await identiﬁ cation.
By contrast, the present study has focused on a 
speciﬁ c functional allele known to aﬀ ect IL6R signalling. 
This meta-analysis has provided large-scale human 
genetic and biomarker evidence that is consistent with a 
causal association between IL6R-related pathways and 
coronary heart disease (panel). First, our results have 
shown that Asp358Ala—a common functional variant 
in IL6R—is unrelated to a panel of conventional 
cardiovascular disease risk factors, suggesting that any 
eﬀ ect of Asp358Ala on risk of coronary heart disease is 
unlikely to be mediated by conventional risk factors. 
Second, we noted that carriage of 358Ala was associated, 
in a dose-dependent manner, with decreased concen-
trations of C-reactive protein and ﬁ brinogen (two 
diﬀ erent liver-derived proteins that sensitively reﬂ ect 
inﬂ ammation status), suggesting that 358Ala dampens 
the systemic inﬂ ammatory response.22 Third, our results 
show that 358Ala is signiﬁ cantly related to decreased risk 
of coronary heart disease in the same dose-dependent 
manner. In aggregate, therefore, these results support 
the inﬂ ammation hypothesis in coronary heart disease 
and encourage exploration of modulation of IL6R path-
ways as a means to prevent coronary heart disease.
Panel: Research in context
Systematic review
The inﬂ ammation hypothesis in coronary heart disease has received potential support 
from human genetic studies that implicate several loci of potential relevance to 
inﬂ ammation in coronary heart disease. However, because the relevant genes (or causal 
variants) in these loci await identiﬁ cation, they do not provide speciﬁ c insight. By contrast, 
the present study has focused on a speciﬁ c functional genetic variant (Asp358Ala; 
rs2228145) known to aﬀ ect interleukin-6 receptor (IL6R) signalling. Previous studies7,23 of 
Asp358Ala, inﬂ ammation biomarkers, and coronary heart disease have been insuﬃ  ciently 
powerful or insuﬃ  ciently detailed, or both, to enable causal evaluation.
In our collaborative meta-analysis, we studied Asp358Ala in IL6R in relation to a panel 
of conventional risk factors and inﬂ ammation biomarkers in 125 222 participants. We 
also compared the frequency of Asp358Ala in 51 441 patients with coronary heart 
disease and in 136 226 controls. These studies were identiﬁ ed by computerised searches 
of electronic databases (eg, PubMed), registries of genetic association studies in 
coronary heart disease, and discussion with investigators. The studies included met 
quality criteria in relation to methods for population sampling, genotyping, biomarker 
assessment, and coronary heart disease outcome deﬁ nition.
Interpretation
358Ala carriers have substantially raised soluble interleukin 6 and IL6R concentrations 
and reduced C-reactive protein and ﬁ brinogen concentrations, which suggests that 
358Ala dampens the systemic inﬂ ammatory response. 358Ala carriers also have reduced 
risk of coronary heart disease. These ﬁ ndings are consistent with a causal role of 
IL6R-related pathways in coronary heart disease, and they support the inﬂ ammation 
hypothesis in this disease.
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Our study has conﬁ rmed previous reports of positive 
associations between circulating interleukin-6 concen-
tration and subsequent risk of coronary heart disease.3,36 
That 358Ala, which is inversely related to coronary 
heart disease, is strongly related with higher concen-
trations of both soluble IL6R and interleukin 6 in a 
dose-dependent manner might, therefore, seem para-
doxical. However, this apparent paradox might be 
resolved by previous suggestions that 358Ala impairs 
classical IL6R signalling by reducing membrane-bound 
IL6R levels, either through increased receptor shedding 
or alternative splicing, rather than by changes in 
production of IL6R or interleukin 6.11–14 Such mechanisms 
could account for the accumulation of both soluble IL6R 
and interleukin 6 in the circulation of people who carry 
358Ala. It would also be consistent with two ﬁ ndings in 
our study. First, expression analyses showed that 
Asp358Ala was not associated with interleukin-6 pro-
duction in several diﬀ erent tissues or in monocytes after 
lipopolysaccharide stimulation. Second, whereas we 
reported positive interrelations among circulating 
concentrations of interleukin 6, C-reactive protein, and 
ﬁ brinogen with one another in the general population, 
carriage of 358Ala was associated with increased inter-
leukin 6 but decreased C-reactive protein and ﬁ brino-
gen concen trations. Nevertheless, further mech anistic 
studies are needed to improve under standing of these 
ﬁ ndings. For example, investigation of 358Ala in rela-
tion to other inﬂ ammation-related phenotypes (and its 
potential eﬀ ects on gp130-mediated trans-signalling) to 
further understand its pleiotropic immuno modulatory 
eﬀ ects would be of particular interest in view of the 
recently reported association of 358Ala with an increased 
risk of asthma.20
Pharmacological agents such as tocilizumab, an 
antihuman monoclonal antibody that competitively 
inhibits IL6R, reduce circulating concentrations of down-
stream inﬂ ammation biomarkers and produce clinical 
beneﬁ ts in rheumatoid arthritis and in other inﬂ am-
matory conditions.37,38 There have also been suggestions 
that such agents improve endothelial function in arthritis 
patients and reduce atherosclerosis in mice.39,40 However, 
whether these agents aﬀ ect risk of coronary heart disease 
is not yet known. Our meta-analysis conﬁ rms that 
tocilizumab use in patients with inﬂ ammatory conditions 
increases LDL and HDL cholesterol and triglyceride 
concentrations. It is uncertain whether such lipid 
changes reﬂ ect improvements in underlying chronic 
inﬂ ammation with tocilizumab, mechanism-based 
eﬀ ects of IL6R modiﬁ cation, or tocilizumab-speciﬁ c 
eﬀ ects.41–43 Hence, the US Food and Drug Administration 
has mandated further study of tocilizumab and 
cardiovascular disease risk factors in postmarketing 
clinical trials.44 Increases in LDL cholesterol with 
tocilizumab might be avoidable, or at least attenuated, 
with concomitant statin use.45,46 However, as shown by 
our meta-analysis, carriage of 358Ala is unrelated to 
concentrations of major lipids, suggesting that 
interleukin-6 modulation might not inherently increase 
these lipids. Further work is needed to understand why 
the eﬀ ect of tocilizumab on major lipids diﬀ ers from that 
of Asp358Ala, despite directionally consistent eﬀ ects on 
inﬂ ammation biomarkers.
The generalisability and validity of our ﬁ ndings have 
been improved by our analysis of genetic and biomarker 
data for more than 200 000 participants. Our observation 
of an association between a single functional variant in 
IL6R and coronary heart disease has been supported by 
a recent replication study of a genome-wide association 
scan.47 By analogy with the fairly small eﬀ ects of 
common variants in LDLR on coronary heart disease 
still being compatible with the major beneﬁ ts of statins 
in coronary heart disease,48 the eﬀ ect of 358Ala on 
coronary heart disease does not necessarily restrict the 
scope for potential therapeutic eﬀ ect of IL6R 
modiﬁ cation in coronary heart disease.49 Future studies 
will seek to study Asp358Ala (or lower frequency 
variants with more pronounced eﬀ ects) in relation to 
additional traits, non-coronary heart disease outcomes, 
and expression studies involving multiple cell types. 
Although our study involves the principle of mendelian 
randomisation, we did not do an instrumental variables 
analysis for two reasons: ﬁ rst, the relevant intermediate 
phenotype of the IL6R pathway remains uncertain 
because Asp358Ala is associated with changes in 
several inﬂ ammation biomarkers; second, our study 
was limited to aggregated (rather than individual-level) 
genetic data.
In conclusion, our data support a causal association 
between IL6R-related pathways and coronary heart 
disease. 
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